The Briefing: Pepperdine’s Trademark Claim Against Netflix in “Running Point” Case Goes Under For Good
Episode 421 -- The Dangers of AI Mistakes
EEO-1 Reports, Remote Work, and Non-Compete Restrictions in Tennessee - Employment Law This Week®
The Briefing: UMG v. Quince: When Trending Audio Becomes Copyright Infringement
Unexpected Paths to IP Law with Kevin MacDonald
New Preorder Patent Owner Rights in Ex Parte Reexamination — Patents: Post-Grant Podcast
The Briefing: Documentary Fair Use After Warhol: The Tenth Circuit Gets It Right
Words Matter: How to Draft Arbitration Agreements That Hold Up in Court - Employment Law This Week®
SkadBytes Podcast | AI Regulation: EU and UK Update and What It Means in Practice
The Briefing: Frida Kahlo vs. The 11th Circuit - A Warning for IP Owners Everywhere
Navigating ICE’s Updated I-9 Audit Guidelines: What Employers Need to Know
At the Intersection of Biotech and AI with Janice Vatland
Podcast - De genérica a icónica: El glow up de una marca
JONES DAY PRESENTS®: Cross-Border Trade Secret Litigation in the U.S. Courts
How Did James Bond Spark a 50-Year Legal War Over Who Owns 007? — No Infringement Intended Podcast
Episode 406 -- AI Risks and Compliance: Building a Governance Framework
The Briefing: Taylor Swift, Trademark Law, and the Fight Over ‘Life of a Showgirl’
DOJ’s Bulk Sensitive Data Transfer Rule: Key Insights for Health Care Compliance Teams – Diagnosing Health Care
SBR-Author’s Podcast: Bribery Beyond Borders: The Hidden History and Future of the FCPA with Severin Wirz
'Urgent National Action to Save College Sports': Trump’s NIL Playbook — Highway to NIL Podcast
On October 17, 2025, USPTO Director John Squires issued a memorandum announcing that he would be sole decision-maker for institution of inter partes review (IPR) and post-grant review (PGR) proceedings....more
In Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (June 4, 2026), a unanimous Supreme Court has further clarified what it takes to plead — and ultimately prove — that a defendant induced another party to infringe a...more
Welcome to WilmerHale’s bulletin on recent trade secret case law and relevant news items. We’ve affectionately nicknamed it “Readily Ascertainable” because, unlike a trade secret, it should be easy to figure out....more
The Supreme Court unanimously ruled in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma Inc., No. 24-889, that a branded pharmaceutical company alleging induced patent infringement against a generic manufacturer must plausibly...more
Key Takeaways: Induced infringement requires clear affirmative conduct. Actions required by law, standard industry practices and omissions do not count as “active steps.”...more
Key Takeaways - Leaving pH measurement conditions undefined let the court apply a default standard temperature, which defeated literal infringement...more
The Federal Circuit’s new precedential decision in Ollnova Technologies Ltd. v. ecobee Technologies ULC may have significant implications for how patent cases are tried, particularly in multi-patent disputes involving...more
On May 4, 2026, the United States Court of Appeals for the Federal Circuit (Judges Lourie, Prost, and District Judge Burroughs) affirmed a decision of the United States District Court for the Eastern District of Arkansas...more
In response to a request for a Director Review of a PTAB decision finding claims 1-4 and 6 of U.S. Patent No. 7,594,168 unpatentable, the Director of the United States Patent and Trademark Office (“USPTO”), on May 1, 2026,...more
On June 4, 2026, Justice Ketanji Brown Jackson, writing for a unanimous Supreme Court of the United States, reversed a decision by the United States Court of Appeals for the Federal Circuit and held that Amarin Pharma, Inc....more
On May 13, 2026, the U.S. Court of Appeals for the Federal Circuit (Judges Reyna, Taranto, and Stoll) affirmed a decision of the U.S. District Court for the Northern District of West Virginia finding that defendant does not...more
Hikma Pharms USA Inc. v. Amarin Pharma, Inc., Appeal No. 24-889 (Sup. Ct. June 4, 2026) - In its first patent case of 2026, the Supreme Court addressed a question of induced infringement as applied to the pharmaceutical...more
Dyson v. Dreame International, UPC_CFI_2255/2025, Hamburg Local Division, April 7, 2026 In April, the UPC granted Dyson Technology Limited (“Dyson”) a new preliminary injunction against several entities within the Dreame...more
Building a successful high-growth startup requires more than just a strong business idea. As venture markets evolve and fundraising timelines shorten, companies with solid legal, governance, and financing foundations will be...more
The manufacture and distribution of generic pharmaceutical drugs is a polarizing topic in the political and legal world. The manufacturing and marketing of generic versions of brand-name drugs are allowed in the United States...more
In a pair of May 2026 decisions, the Federal Circuit offered important guidance on what rights a patent owner must retain in a licensed patent and still have standing to sue. In a precedential opinion involving A.L.M. Holding...more
On June 2, 2026, President Trump signed an Executive Order titled "Promoting Advanced Artificial Intelligence Innovation and Security" (the "Order"). The Order represents the Administration's latest action in its broader...more
The UPC Court of Appeal has delivered an important ruling in Fujifilm v Kodak, confirming that the Unified Patent Court’s jurisdiction may extend to non-UPC European patent designations. The decision distinguishes between the...more
As data centers integrate numerous advanced technologies within a single operating environment, they are becoming a natural focal point for intellectual property (IP) scrutiny, including patent disputes, with patent...more
By now most people have heard that Hikma v. Amarin, No. 24–889 (June 4, 2026), was an overall favorable decision for skinny labeling. But what are the practical takeaways? Here we outline the facts and factors considered by...more
AI-Assisted Development Is Reshaping Software Ownership, Confidentiality and Litigation Risk - Artificial intelligence (AI) is rapidly transforming how software is developed. More than ever, engineers are no longer writing...more
In a unanimous opinion by Justice Ketanji Brown Jackson, the U.S. Supreme Court held that Amarin, the developer of Vascepa® (reference listed drug), failed to plausibly allege that Hikma actively induced infringement of...more
In April 2026, a complaint alleging “one of the most egregious examples of piracy in the medical technology industry” landed on the docket of the U.S. District Court for the Eastern District of Texas....more
Key Takeaways: In Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889, the Supreme Court reversed the Federal Circuit and held that a generic drug manufacturer’s FDA-compliant skinny label, combined with...more
On June 4, 2026, the United States Supreme Court issued its decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. In its decision, the Supreme Court reversed the Federal Circuit, and held that Amarin’s complaint...more